Novavax (NVAX)
Your Dashboard
Displaying NVAX Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 2.959M
- Accounts Receivable 3.134M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.2681
- Beneish M-Score Pro
- Beta Pro
- Book Value 54.32M
- Book Value per Share 0.4469
- Capital Expenditures 0.772M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing 7.259M
- Cash Financing TTM 17.04M
- Cash Investing -3.27M
- Cash Investing TTM 7.288M
- Cash Operations -4.22M
- Cash Operations TTM -18.81M
- Cash and Equivalents 13.87M
- Cash and ST Investments 20.72M
- Current Ratio 3.372
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.0075
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.06
- Earnings Per Share Growth
- Earnings Per Share TTM -0.16
- Earnings Yield -12.96%
- Effective Tax Rate TTM Pro
- Enterprise Value 142.14M
- Expenses 11.98M
- Expenses TTM 37.74M
- Free Cash Flow -4.992M
- Free Cash Flow TTM -20.15M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 18.44%
- Gross Profit TTM 8.05M
- Income from Cont. Ops Pro
- Interest Expense 0.003M
- Interest Income 0.033M
- Inventories
- KZ Index Pro
- Liabilities 14.31M
- Long Term Debt 0.40M
- Market Cap 150.14M
- Net Income -7.336M
- Net Income TTM -19.25M
- Net PP&E 7.949M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 1.235
- Price / Book Value 2.764
- Price / Sales Ratio 8.117
- Price / Tangible Book Value Pro
- Profit Margin -158.0%
- R&D Expense 5.077M
- Receivables Turnover 5.137
- Retained Earnings -336.99M
- Retained Earnings Growth
- Return on Assets -28.16%
- Return on Equity -35.31%
- Return on Invested Capital Pro
- Revenue Growth 456.6%
- Revenue Per Share TTM 0.1521
- Revenues 4.642M
- Revenues TTM 18.50M
- SG&A Expense 3.246M
- Shareholders Equity 54.32M
- Shares Outstanding 121.57M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 68.64M
- Total Return Price 1.235
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these NVAX related companies
NVAX News
NOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
May 09, 8:04AM Benzinga
May 09, 8:04AM Benzinga
$ZGNX and $GERN becoming even more interesting now $NVAX not so bad today
about 23 days ago by micheleciani
about 23 days ago by micheleciani
Market Wrap Video + Additions to Watch List http://stks.co/3iY4 including: $CAR $CPTS $GWR $NVAX $PBY $PPR
about 23 days ago by StockTiger
about 23 days ago by StockTiger
$NVAX http://stks.co/3iCA for a move to 200-day ok % gain if so -n Over $1.44 to 200-day
about 23 days ago by StockTiger
about 23 days ago by StockTiger
@Bleedblue i own both lol and $GALE is making me sad but $NVAX is making me happy
about 23 days ago by MisterDevin
about 23 days ago by MisterDevin
Listen to $NVAX Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3flk
about 27 days ago by earningscast
about 27 days ago by earningscast
$NVAX Reports First Quarter 2012 Financial Results http://stks.co/3fh4 Good
about 27 days ago by micheleciani
about 27 days ago by micheleciani
Stock on our radar $ZGNX and $NVAX both more than +10% in the last few days
about 28 days ago by micheleciani
about 28 days ago by micheleciani
NOVAVAX Launches Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
May 02, 8:08AM Benzinga
May 02, 8:08AM Benzinga
Novavax (NVAX) Commences Enrollment in A/H5N1 Vaccine Candidate Phase I
May 02, 8:03AM Street Insider
May 02, 8:03AM Street Insider
@JVerns Yea. $NVAX not bad, a lot of volume, been holding that for a while. $GALE has huge upside, long wait though, I'll just cont. to add
about 30 days ago by MisterDevin
about 30 days ago by MisterDevin
@MisterDevin In the same boat. $NVAX could get even more interesting tomorrow
about 30 days ago by JVerns
about 30 days ago by JVerns
NOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections
Mar 22, 9:52AM GlobeNewswire
Mar 22, 9:52AM GlobeNewswire
NOVAVAX Appoints John A. Herrmann III, Vice President and General Counsel
Mar 08, 9:00AM GlobeNewswire
Mar 08, 9:00AM GlobeNewswire
Novavax (NVAX) Commences Enrollment in Quadrivalent Seasonal VLP Phase II
Mar 01, 4:34PM Street Insider
Mar 01, 4:34PM Street Insider
NOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012
Feb 24, 8:00AM GlobeNewswire
Feb 24, 8:00AM GlobeNewswire
Novavax (NVAX) India JV Makes Significant Vaccine-Development Program Progress
Jan 03, 8:17AM Street Insider
Jan 03, 8:17AM Street Insider
NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals
Jan 03, 8:06AM Benzinga
Jan 03, 8:06AM Benzinga
NOVAVAX to Present at 23rd Annual Piper Jaffray Health Care Conference
Nov 28, 12:17PM GlobeNewswire
Nov 28, 12:17PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NVAX | 1.235 | -0.04 | -3.52% | 155.61M |
| NUV | 10.23 | +0.02 | +0.20% | |
| NUTR | 14.97 | -0.13 | -0.86% | 150.09M |
| NUS | 43.53 | +0.04 | +0.09% | 2.747B |
| NUROD | 0.74 | -0.01 | -1.33% | |
| NURO | 0.72 | -0.02 | -2.70% | 9.198M |
| NUO | 17.50 | +0.01 | +0.06% | |
| NUM | 15.41 | -0.01 | -0.06% | |
| NUE | 35.90 | -0.71 | -1.94% | 11.61B |
| NUCL | 31.31 | +0.16 | +0.52% |
